Drug Profile
Traneurocin - NeuroActiva
Alternative Names: BIOCOVAX; BIOMEDIVIR; DEXANEUROSONE; NA 831; NA-81; NANOMEDIVIR; NEUROSIVIR; TRANEUROCINELatest Information Update: 06 Oct 2023
Price :
$50
*
At a glance
- Originator NeuroActiva
- Developer Biomed Industries; Florey Institute of Neuroscience and Mental Health; NeuroActiva
- Class Antidementias; Antidepressants; Neuroprotectants; Nootropics; Peptides
- Mechanism of Action AMPA receptor agonists; Neurogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III COVID 2019 infections
- Phase II Alzheimer's disease; Fragile X syndrome; Rett syndrome
- Phase I Major depressive disorder
- No development reported Neurological disorders
Most Recent Events
- 06 Oct 2023 Phase-II clinical trials in Fragile X syndrome (unspecified route) (Biomed Industries pipeline, October 2023)
- 06 Oct 2023 Phase-II clinical trials in Rett syndrome (unspecified route) (Biomed Industries pipeline, October 2023)
- 05 Oct 2023 Biomed Industries plans a phase II trial for Alzheimer’s Disease (Combination therapy)